Spots Global Cancer Trial Database for Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
Official Title: Phase 1 Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of Intravenously Administered SNS-032 Injection, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Advanced B-Lymphoid Malignancies
Study ID: NCT00446342
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
Detailed Description: Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the body) and identifying potential biomarkers.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope, Duarte, California, United States
Stanford Cancer Center, Stanford, California, United States
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Hackensack University Medical Center at the Cancer Center, Hackensack, New Jersey, United States
MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
Contact Details
Name: Glenn Michelson, MD
Affiliation: Sunesis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
